These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 28576749)

  • 41. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
    Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
    Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
    Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
    Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
    Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
    Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
    Li T; Guo T; Liu H; Jiang H; Wang Y
    Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
    Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
    Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
    Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
    Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.
    Gao Y; Packeiser EM; Wendt S; Sekora A; Cavalleri JV; Pratscher B; Alammar M; Hühns M; Brenig B; Junghanss C; Nolte I; Murua Escobar H
    Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
    Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
    Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A combinatorial strategy for treating KRAS-mutant lung cancer.
    Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
    Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
    Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
    Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
    Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
    Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
    Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
    Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
    Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.